Objectives
hormone-refractory, tumor
SECONDARY, METASTATIC BREAST CANCER, EVENT, TUMOR
Previous work showed that PET-CT can predict early response to endocrine therapy [The primary objective of the study was to evaluate the efficacy of naltrexone for the treatment of hormone-refractory, metastatic breast cancer as measured by [18 F] fluorodeoxyglucose (FDG) PET-CT SUVmax after 4 weeks. The secondary objectives were to evaluate the safety of naltrexone in the treatment of hormone-refractory, metastatic breast cancer (as assessed by CTCAE version 3.0), tumor response by SUVmax at 8 weeks, and to determine the median time to event (first time when SUVmax is higher than that at baseline) within one year from enrollment.